infect
remain
caus
signific
morbid
mortal
follow
hematopoiet
stem
cell
transplant
hsct
condit
regimen
chemotherapi
radiat
therapi
mucos
damag
type
transplant
immun
suppress
therapi
graftversushost
diseas
gvhd
predispos
hsct
recipi
infect
abnorm
band
tlymphocyt
function
result
impair
humor
cellular
immun
respect
neutrophil
function
impair
use
corticosteroid
medic
hypogammaglobulinemia
function
asplenia
common
occurr
infect
individu
patient
vari
accord
phase
transplant
process
reflect
type
immun
defect
underli
diseas
endogen
host
flora
exposur
histori
pretreat
infect
first
neutropen
fever
comprehens
fever
workup
includ
follow
addit
test
prompt
local
signssymptom
blood
cultur
peripher
blood
draw
well
lumen
central
cathet
ii
urin
analysi
ua
dipmicro
urin
cultur
iii
sputum
cultur
patient
cough
abl
expector
sampl
iv
twoview
chest
xray
cxr
evalu
pulmonari
infect
b
discontinu
prophylact
antibiot
begin
empir
parenter
antibiot
therapi
soon
possibl
alway
within
h
initi
fever
empir
antibiot
therapi
suffici
broad
provid
coverag
p
aeruginosa
enterobacteriacea
oral
streptococci
ii
option
includ
cefepim
fourth
gener
cephalosporin
piperacillintazobactam
antipseudomon
carbapenem
e
g
meropenem
imipenem
iii
consider
local
institut
antibiogram
well
patientspecif
histori
prior
drugresist
bacteria
critic
import
determin
empir
antibiot
select
iv
septicclin
unstabl
patient
consid
broaden
empir
regimen
includ
aminoglycosid
eg
tobramycin
mgkg
intraven
iv
daili
adjust
renal
function
oncedaili
dose
prefer
well
extend
gramposit
coverag
see
sect
lipidbas
amphotericin
product
mgkg
iv
h
echinocandin
though
recogn
inferior
agent
prophylaxistreat
mold
infect
patient
receiv
posaconazol
prophylaxi
obtain
ct
chest
check
serum
galactomannan
send
posaconazol
level
yet
sent
ct
chest
suspici
fungal
infect
serum
galactomannan
posit
consid
switch
altern
agent
eg
voriconazol
lipidbas
amphotericin
product
consult
pulmonari
servic
consider
diagnost
bronchoscopi
andor
diagnost
test
e
patient
receiv
voriconazol
clinic
suspicion
invas
mold
infect
entertain
possibl
subtherapeut
voriconazol
level
voriconazoleresist
organ
consid
empir
chang
lipidbas
amphotericin
product
ambisom
abelcet
voriconazol
level
check
prior
drug
discontinu
see
tabl
paramount
import
treatment
infect
hsct
recipi
abil
obtain
accur
diagnosi
symptom
infect
may
nonspecif
even
attenu
heavili
immun
suppress
hsct
recipi
diagnosi
infect
may
requir
cultur
blood
bodi
fluid
molecular
diagnost
test
eg
polymeras
chain
reaction
pcr
radiograph
studi
invas
diagnost
obtain
tissu
materi
well
care
ongo
assess
chang
clinic
statu
rate
occurr
decreas
acyclovir
relat
congen
prophylaxi
b
typic
occur
month
posttranspl
later
allogen
recipi
may
associ
viscer
central
nervou
system
diseas
c
may
local
singl
dermatom
dissemin
see
fig
thorough
skin
examin
recommend
evalu
dissemin
diseas
oral
antivir
therapi
acyclovir
mg
oral
po
five
time
daili
adjust
dose
renal
function
standard
care
lesion
confin
singl
dermatom
valacyclovir
valtrex
achiev
better
therapeut
plasma
level
vzv
may
use
prefer
altern
oral
acyclovir
cost
preclud
use
dose
mg
po
three
time
daili
tid
renal
dose
adjust
indict
see
tabl
e
sever
herp
zoster
infect
dermatom
trigemin
nerv
involv
viscer
dissemin
diseas
patient
hospit
treat
intraven
acyclovir
mgkg
iv
everi
h
renal
dose
adjust
indic
see
tabl
lesion
complet
crust
new
lesion
evid
transit
oral
compound
acyclovir
valacyclovir
complet
treatment
cours
monitor
acut
kidney
injuri
encephalopathi
possibl
advers
effect
highdos
parenter
acyclovir
f
acyclovirresist
vzv
rel
unusu
suspect
viral
cultur
obtain
phenotyp
resist
test
consider
use
foscarnet
mgkg
iv
everi
h
renal
dose
adjust
indic
resist
proven
context
lifethreaten
infect
await
result
resist
test
along
consult
infecti
diseas
servic
infect
larg
relat
reactiv
posttranspl
set
absent
prophylaxi
occur
earli
within
first
month
posttranspl
b
risk
infect
decreas
acyclovir
relat
congen
prophylaxi
c
infect
often
present
sever
mucos
occasion
esophag
less
often
secondari
infect
variou
organ
context
viremia
infect
less
common
typic
affect
genitalperinealbuttock
region
nonsever
infect
limit
mucou
membran
oral
antivir
therapi
usual
adequ
acyclovir
mg
po
five
time
daili
approxim
day
unabl
toler
oral
medic
use
acyclovir
mg
kg
iv
everi
h
approxim
day
altern
therapi
includ
valacyclovir
mg
po
two
time
daili
bid
day
e
case
suspectedproven
viscer
dissemin
eg
enceph
hepat
pneumon
acyclovir
mgkg
iv
everi
h
use
initi
therapi
durat
typic
day
depend
clinic
syndrom
clinic
cours
f
select
patient
frequent
recur
outbreak
may
requir
chronic
antivir
suppress
follow
regimen
accept
acyclovir
mg
po
bidtid
valacyclovir
mg
po
bid
g
drug
dose
renal
adjust
indic
see
tabl
infect
almost
univers
relat
reactiv
occur
transplant
recipi
earli
posthsct
period
week
b
viremia
often
asymptomat
though
purport
associ
varieti
nonspecif
present
eg
bone
marrow
suppress
delirium
causal
associ
enceph
support
numer
case
report
case
seri
c
enceph
suspect
pcr
test
cerebrospin
fluid
csf
blood
perform
magnet
reson
imag
mri
brain
may
reveal
abnorm
often
involv
tempor
lobe
treatment
controversi
establish
enceph
foscarnet
ganciclovir
use
therapeut
dose
treatment
decis
made
casebycas
basi
consult
infecti
diseas
servic
cmv
infect
lead
endorgan
diseas
hsct
recipi
manifest
pneumonia
gastroenter
hepat
retin
enceph
etc
b
detect
cmv
pcr
blood
context
clinic
sign
symptom
consist
cmv
diseas
suggest
certain
diagnosi
typic
requir
diagnost
bronchoscopi
andor
tissu
biopsi
furthermor
cmv
pcr
detect
blood
fulli
sensit
detect
endorgan
diseas
particularli
gastrointestin
diseas
cmv
diseas
suspect
tissu
biopsi
histopatholog
viral
cultur
obtain
feasibl
c
cmv
endorgan
diseas
suspectedproven
consult
infecti
diseas
servic
patientspecif
treatment
recommend
advis
firstlin
therapi
cmv
diseas
gener
iv
ganciclovir
foscarnet
reserv
case
intoler
ganciclovir
eg
refractori
cytopenia
ganciclovir
resist
suspect
eg
cmv
viral
load
increas
therapi
week
document
ganciclovirresist
viru
unusu
occurr
hsct
popul
often
occur
patient
prolong
exposur
ganciclovir
valganciclovir
e
treatment
durat
determin
casebycas
basi
take
consider
sever
cmv
diseas
immun
statu
host
typic
induct
dose
given
least
week
cmv
viral
load
undetect
symptom
endorgan
diseas
resolv
sever
week
mainten
iv
ganciclovir
oral
valganciclovir
dose
thereaft
see
tabl
dose
f
cmv
pneumonia
addit
antivir
therapi
adjuv
immun
globulin
gener
recommend
larg
base
small
uncontrol
studi
though
recent
analys
rais
question
valu
intervent
cmvspecif
immun
globulin
shown
effect
intraven
immunoglobulin
ivig
costli
ii
dose
frequenc
durat
ivig
cmv
pneumonia
well
studi
histor
ivig
dose
mgkg
iv
everi
day
ten
dose
adenoviru
bk
viru
result
hemorrhag
cystiti
posttranspl
b
patient
develop
bk
viral
cystiti
initi
approach
consist
support
care
begin
antispasmot
eg
oxybutinin
urinari
tract
analges
eg
phenazopyridin
ii
consid
reduc
immun
suppress
feasibl
begin
continu
bladder
irrig
symptom
control
antispasmot
iii
patient
develop
fulmin
hemorrhag
cystiti
consid
therapi
cidofovir
varieti
cidofovir
dose
protocol
report
case
report
small
case
seri
eg
mgkg
weekli
three
time
weekli
without
probenecid
goal
minim
drug
toxic
import
advers
drug
effect
associ
cidofovir
administr
includ
nephrotox
well
hematolog
ocular
toxic
care
monitor
recommend
set
iv
viral
load
quantif
correl
symptom
clinic
signific
viral
load
unknown
c
adenoviru
infect
manifest
hemorrhag
cystiti
significantli
like
bk
viru
result
dissemin
potenti
lifethreaten
diseas
adenoviru
affect
lung
gastrointestin
tract
liver
gu
system
andor
central
nervou
system
ii
patient
posit
cultur
pcr
adenoviru
urin
blood
sent
quantit
adenoviru
pcr
iii
adenoviru
virem
patient
andor
set
fulmin
hemorrhag
cystiti
strong
consider
given
system
treatment
cidofovir
mgkg
iv
weekli
week
everi
week
mgkg
three
time
weekli
renal
dose
adjust
indic
system
dissemin
diseas
eg
diseas
outsid
gu
tract
suspect
add
probenecid
g
po
h
prior
cidofovir
dose
g
po
h
dose
commun
respiratori
viral
infect
commun
respiratori
viral
infect
common
hsct
recipi
result
spectrum
clinic
find
upper
respiratori
tract
infect
uri
lower
respiratori
tract
infect
lrti
often
seriou
associ
morbid
even
mortal
addit
direct
effect
viral
infect
increas
risk
coinfect
eg
bacteria
fungi
set
well
risk
late
airflow
obstruct
commun
respiratori
virus
distinct
season
eg
influenza
respiratori
syncyti
viru
rsv
other
occur
year
round
eg
rhinoviru
test
commun
respiratori
viral
infect
molecular
methodsmultiplex
pcr
nasopharyng
sampl
lower
respiratori
tract
sampl
methodolog
offer
highest
sensit
diagnosi
evalu
suspect
lrti
patient
uri
includ
chest
imag
cxr
andor
ct
chest
droplet
contact
precaut
initi
hospit
patient
either
suspect
document
commun
respiratori
viral
infect
use
airborn
precaut
context
aerosolgener
procedur
eg
bilevel
posit
airway
pressur
bipap
suction
etc
precaut
continu
patient
asymptomat
repeat
test
viral
infect
neg
inhal
ribavirin
use
patient
must
neg
airflow
room
airborn
isol
rsv
rsv
lrti
patient
receiv
ribavirin
mgml
gm
h
everi
h
day
use
viratek
small
particl
gener
face
mask
endotrach
tube
adjuv
ivig
mgkg
qod
dose
ii
consid
inhal
ribavirin
therapi
along
ivig
administr
allogen
recipi
absolut
lymphocyt
count
alc
cellsmm
andor
steroid
dose
mgkgday
prednison
equival
present
rsv
uri
goal
prevent
progress
lrti
acknowledg
howev
limit
data
approach
iii
limit
data
case
seri
uncontrol
studi
use
system
oral
intraven
ribavirin
treatment
rsv
infect
initi
therapi
appropri
antivir
agent
soon
possibl
two
main
class
drug
neuraminidas
inhibitor
eg
osteltamivir
zanamavir
inhibitor
eg
amantadin
rimantadin
antivir
therapi
influenza
vari
depend
drug
resist
pattern
circul
strain
durat
therapi
neuraminidas
inhibitor
typic
day
though
longer
durat
therapi
day
may
consid
hospit
patient
sever
influenza
infect
ii
unvaccin
caregiv
patient
expos
case
document
influenza
refer
chemoprophylaxi
soon
possibl
within
h
exposur
drug
resist
pattern
circul
influenza
strain
guid
choic
antivir
prophylaxi
iii
context
signific
commun
outbreak
transmiss
transplant
unittranspl
clinic
polici
chemoprophylaxi
discuss
infecti
diseas
serviceinfect
control
consid
base
drug
resist
pattern
circul
influenza
strain
c
adenoviru
system
cidofovir
strongli
consid
context
invas
adenoviru
infect
data
optim
dose
cidofovir
avail
usual
practic
use
mgkg
iv
weekli
renal
dose
adjust
indic
week
everi
week
set
lifethreaten
dissemin
diseas
along
probenecid
g
po
h
prior
cidofovir
dose
g
po
h
dose
import
advers
drug
effect
associ
cidofovir
administr
includ
nephrotox
well
hematolog
ocular
toxic
care
monitor
recommend
set
ii
possibl
immun
suppress
reduc
set
lifethreaten
dissemin
adenoviru
diseas
ebv
result
posttranspl
lymphoprolif
diseas
ptld
manifest
fever
adenopathi
andor
extranod
diseas
b
quantit
ebv
pcr
blood
andor
bodi
fluid
eg
csf
may
support
diagnosi
though
certain
diagnosi
requir
tissu
biopsi
immunohistochemistri
c
ebv
viral
load
monitor
recommend
certain
highrisk
hsct
recipi
though
threshold
preemptiv
intervent
clear
patient
receiv
cell
deplet
cord
blood
haploident
stem
cell
product
expos
antithymocyt
globulin
atg
consid
preemptiv
monitor
quantit
ebv
viral
load
monitor
firstlin
therapi
establish
ptld
administr
monoclon
antibodi
rituximab
infus
ebvspecif
cytotox
tlymphocyt
use
success
variou
studi
protocol
though
requir
signific
time
vitro
gener
littl
evid
time
support
contribut
antivir
therapi
indic
infect
rare
patient
compliant
firstlin
pcp
prophylaxi
eg
trimethoprimsulfamethoxazol
breakthrough
infect
possibl
particular
patient
firstlin
agent
b
radiograph
studi
chest
ct
cxr
typic
reveal
diffus
interstiti
infiltr
ground
glass
appear
although
appear
quit
vari
c
diagnosi
typic
visual
organ
respiratori
specimen
microscopi
stain
induc
sputum
bronchoalveolar
lavag
bal
specimen
still
consid
investig
pcr
bal
fluid
induc
sputum
increas
diagnost
yield
convent
microscopi
time
lung
biopsi
requir
make
diagnosi
firstlin
treatment
trimethoprimsulfamethoxazol
mgkgday
renal
dose
adjust
indic
trimethoprim
equival
divid
daili
dose
day
e
case
signific
sulfa
allergi
intoler
altern
therapi
includ
pentamidin
mgkgday
iv
renal
dose
adjust
indic
day
sever
diseas
clindamycin
mg
po
everi
h
primaquin
mg
base
po
daili
mild
moder
diseas
uniqu
side
effect
associ
daili
pentamidin
therapi
includ
hypotens
hypoor
hyperglycemia
pancreat
andor
cardiac
arrhythmia
f
context
moder
sever
diseas
adjunct
corticosteroid
consid
though
recogn
direct
data
intervent
hivneg
popul
lack
patient
partial
pressur
arteri
oxygen
pao
mmhg
andor
alveolararteri
oxygen
gradient
mmhg
andor
hypoxemia
puls
oximetri
prednison
mg
po
bid
day
mg
po
daili
day
mg
po
daili
day
consid
combin
antimicrobi
therapi
patient
alreadi
receiv
steroid
compar
dosag
ii
patient
corticosteroid
time
pcp
diagnosi
eg
gvhd
continu
current
regimen
risk
toxoplasmosi
follow
allogen
hsct
depend
seropreval
popul
condit
regimendegre
immun
suppress
seropreval
studi
indic
us
popul
previous
infect
toxoplasmosi
toxoplasmosi
transplant
hsct
recipi
reactiv
diseas
b
toxoplasmosi
often
affect
central
nervou
system
also
present
dissemin
infect
hsct
recipi
ct
mri
brain
may
reveal
focal
mass
lesion
less
commonli
diffus
enceph
c
toxoplasmosi
suspect
toxoplasma
pcr
csf
andor
blood
obtain
tissu
biopsi
often
necessari
establish
certain
diagnosi
given
often
nonspecif
present
dissemin
toxoplasmosi
high
index
suspicion
diagnosi
maintain
particular
seroposit
individu
treatment
establish
diseas
due
toxoplasmosi
includ
pyrimethamin
mg
load
dose
day
mg
po
daili
patient
kg
mg
po
daili
patient
kg
ii
sulfadiazin
mg
po
four
time
daili
patient
kg
mg
po
four
time
daili
patient
kg
iii
folin
acid
mg
po
daili
e
patient
toler
sulfadiazin
due
signific
allergi
contraind
pyrimethamin
folin
acid
plu
clindamycin
mg
poiv
four
time
daili
qid
azithromycin
mg
po
daili
use
f
patient
toler
pyrimethamin
sulfadiazin
plu
atovaquon
mg
po
bid
use
salvag
singleag
atovaquon
unabl
toler
either
sulfadiazin
pyrimethamin
g
durat
therapi
typic
week
follow
cours
suppress
therapi
howev
individu
base
clinicalradiograph
respons
h
toxoplasmaseroposit
transplant
candidatesrecipi
receiv
trimethoprimsulfamethoxazol
pcp
prophylaxi
given
protect
provid
toxoplasmosi
presum
signific
allergi
strict
contraind
c
difficil
frequent
caus
infecti
diarrhea
among
hospit
patient
particularli
hsct
recipi
owe
often
long
hospit
receipt
broadspectrum
antibiot
chemotherapyinduc
gut
disrupt
incid
c
difficil
follow
transplant
recent
larg
singlecent
studi
alonso
et
al
suggest
strong
interact
gastrointestin
gvhd
c
difficil
b
c
difficil
consid
hsct
recipi
newworsen
diarrhea
caveat
diarrhea
common
posthsct
broad
differenti
diagnosi
c
laboratori
diagnosi
c
difficil
typic
demonstr
c
difficil
toxin
number
test
avail
broad
clinic
use
pcr
toxin
b
enzym
immunoassay
eia
c
difficil
toxin
b
eia
c
difficil
glutam
dehydrogenas
gdh
enzym
produc
toxigen
nontoxigen
c
difficil
strain
pcr
sensit
eia
toxin
b
potenti
fals
posit
result
ii
eia
gdh
sensit
specif
iii
laboratori
favor
use
tier
screen
eia
gdh
first
test
reflex
eia
andor
pcr
toxin
b
gdh
test
posit
gener
principl
manag
includ
discontinu
narrow
antibacteri
abl
fluid
electrolyt
support
avoid
antiperistalt
agent
eg
loperimid
diphenoxylateatropin
institut
appropri
infect
control
measur
contact
precaut
strict
hand
hygien
antibacteri
soap
water
environment
clean
bleach
etc
antimicrobi
therapi
c
difficil
e
two
main
drug
use
treatment
c
difficil
oral
metronidazol
oral
vancomycin
oral
metronidazol
mg
poiv
q
h
use
mildtomoder
diseas
ii
oral
vancomycin
mg
po
qid
per
rectum
ileu
present
sever
diseas
iii
sever
complic
c
difficil
ileu
megacolon
etc
mani
provid
use
combin
oral
vancomycin
often
high
dose
mg
qid
intraven
metronidazol
mg
iv
q
h
iv
durat
therapi
least
day
patient
indic
antibiot
therapi
provid
often
choos
extend
cours
c
difficileact
therapi
fix
period
eg
week
follow
discontinu
antibacteri
v
paramet
still
defin
use
fidaxomicin
antibiot
bactericid
c
difficil
shown
phase
studi
patient
nonsever
c
difficil
infect
lower
recurr
rate
vancomycin
cost
remain
major
barrier
use
agent
f
earli
surgic
evalu
obtain
patient
sever
complic
c
difficil
colectomi
aggress
potenti
lifesav
intervent
g
recurr
initi
infect
uncommon
affect
mani
patient
manag
first
recurr
guid
principl
first
infect
often
prolongedtap
cours
oral
vancomycin
patient
multipl
recurr
h
patient
multipl
c
difficil
recurr
fecal
microbiota
transplant
consid
though
caveat
avoid
patient
neutropen
earli
posttranspl
eg
month
highdos
immun
suppress
activ
gvhd
gut
mucos
disrupt
experi
limit
case
report
data
longterm
outcomessequnc
lack
time
secondari
prophylaxi
use
c
difficileact
therapi
patient
histori
c
difficil
subsequ
requir
prophylact
treatment
antibiot
sometim
use
provid
though
point
prospect
data
support
practic
note
prolong
oral
metronidazol
advis
given
risk
emerg
drug
toxic
eg
peripher
neuropathi
neutropenia
protract
use
infect
candida
speci
classifi
invas
eg
candidemia
hepatosplen
candidiasi
etc
superfici
eg
mucos
era
widespread
use
azol
prophylaxi
candidiasi
occur
rel
infrequ
hsct
popul
howev
fluconazoleresist
candida
speci
c
krusei
c
glabrata
particular
concern
candidemia
echinocandin
micafungin
mg
iv
daili
caspofungin
mg
iv
load
mg
iv
daili
anidulafungin
mg
iv
load
mg
iv
daili
amphotericin
b
lipidbas
product
dose
mgkg
iv
daili
recommend
empir
treatment
candidemia
neutropen
host
await
specieslevel
identif
guid
therapi
patient
critic
ill
without
recent
azol
exposur
highdos
fluconazol
mg
poiv
load
dose
follow
mg
poiv
daili
consid
voriconazol
mg
kg
po
bid
two
dose
load
follow
mgkg
po
bid
mold
coverag
also
desir
ii
specieslevel
identif
antifung
suscept
data
avail
antifung
therapi
adjust
infect
due
c
albican
c
parapsilosi
either
fluconazol
amphotericinbas
product
accept
fluconazol
less
toxic
conveni
choic
patient
stabil
infect
due
c
glabrata
echinocandin
often
prefer
though
acknowledg
recent
report
emerg
echinocandin
resist
amphotericinbas
therapi
less
attract
option
light
potenti
toxic
infect
due
c
krusei
either
echinocandin
voriconazol
lipid
formul
amphotericin
gener
accept
iii
durat
therapi
candidemia
week
document
clearanc
blood
cultur
resolut
neutropenia
provid
concern
deepseat
foci
persist
posit
blood
cultur
iv
remov
vascular
cathet
strongli
consid
set
candidemia
though
acknowledg
gut
transloc
sourc
infect
v
ophthalmolog
consult
obtain
evalu
candida
endophthalm
ct
abdomen
consid
evalu
hepatosplen
candidiasi
see
sect
appropri
clinic
set
vi
highgrad
persist
candidemia
echocardiogram
obtain
evalu
endocard
b
chronic
dissemin
candidiasi
syndrom
also
refer
hepatosplen
candidiasi
often
seen
soon
recoveri
neutropenia
ii
c
albican
often
caus
organ
speci
seen
far
less
often
iii
present
signssymptom
often
vagu
malais
fever
andor
nonspecif
gastrointestin
complaint
iv
diagnosi
suggest
elev
serum
alkalin
phosphatas
andor
multipl
hepat
hypodens
seen
abdomin
ct
blood
cultur
often
neg
v
definit
diagnosi
establish
liver
biopsi
classic
demonstr
multipl
granuloma
visual
yeast
hyphal
element
special
stain
often
cultur
tissu
liver
biopsi
neg
particularli
patient
receiv
antifung
therapi
vi
molecular
diagnost
studi
eg
fungal
pcr
offer
addit
sensit
provid
specieslevel
inform
vii
treatment
consider
includ
azol
therapi
frequent
fluconazol
c
albican
common
speci
implic
set
echinocandin
lipidbas
amphotericin
product
bulk
avail
data
amphotericin
b
deoxychol
fluconazol
treatment
decis
base
previou
antifung
therapi
avail
microbiolog
data
viii
durat
therapi
typic
prolong
mani
month
guid
clinic
respons
radiograph
resolut
calcif
c
candida
cystiti
consid
whether
urin
cultur
candida
speci
repres
colon
infect
base
whether
patient
display
sign
andor
symptom
urinari
tract
infect
uti
ii
patient
indwel
cathet
remov
remov
exchang
cathet
repeat
urin
studi
iii
treatment
candiduria
indic
neutropen
host
whether
symptomat
asymptomat
iv
fluconazol
mg
poiv
daili
day
treatment
choic
candid
cystiti
due
fluconazolesensit
organ
treatment
cystiti
due
fluconazoleresist
organ
eg
c
krusei
c
glabrata
amphotericin
b
deoxychol
use
either
system
low
dose
bladder
irrig
one
note
urinari
tract
drug
level
lipid
formul
amphotericin
b
high
enough
provid
adequ
treatment
voriconazol
effect
drug
candid
cystiti
given
activ
drug
excret
urin
signific
amount
although
echinocandin
achiev
low
concentr
urin
limit
data
describ
success
use
antifung
agent
treatment
renal
parenchym
infect
v
patient
recurr
seemingli
complic
candida
cystiti
renal
ultrasound
perform
evalu
fungal
mass
would
entail
system
antifung
therapi
well
consider
surgic
approach
oropharyng
candidiasi
topic
therapi
nystatin
suspens
ml
unitsml
swish
spitswallow
qid
clotrimazol
troch
mg
dissolv
mouth
time
per
day
first
line
use
system
therapi
azol
echinocandin
lowdos
amphotericin
b
lipidbas
product
moder
sever
diseas
aspergillu
fumigatu
common
aspergillu
speci
implic
caus
infect
immunocompromis
host
though
speci
also
result
invas
infect
b
pulmonari
infect
common
present
sinu
diseas
andor
hematogen
dissemin
organ
involv
eg
central
nervou
system
sinus
skin
etc
seen
occas
c
key
success
manag
earli
consider
process
imag
appropri
diagnost
evalu
along
prompt
initi
antifung
therapi
chest
imag
suggest
appropri
context
proven
probabl
diagnosi
requir
mycolog
diagnosi
either
cultur
fungal
biomark
e
diagnosi
pulmonari
infect
often
establish
use
aspergillu
galactomannan
test
bronchoalveolar
lavag
fluid
diagnosi
obtain
less
invas
mean
surgic
biopsi
consid
f
voriconazol
firstlin
therapi
invas
aspergillosi
voriconazol
trough
level
measur
earli
patient
proven
probabl
invas
aspergillosi
poor
respons
treatment
possibl
side
effect
therapi
suspicion
poor
oral
absorpt
complex
drugdrug
interact
see
tabl
dose
guidelin
trough
target
g
signific
increas
serum
transaminas
level
note
voriconazol
therapi
time
upper
limit
normal
check
voriconazol
level
consid
chang
lipidbas
amphotericin
product
posaconazol
mg
po
qid
x
week
mg
po
bid
suspens
care
monitor
posaconazol
delayedreleas
tablet
appear
offer
better
oral
bioavail
suspens
conveni
daili
dose
initi
load
mg
po
bid
day
mg
daili
tablet
formul
dose
schema
studi
approv
prophylaxi
approach
consid
treatment
patient
refractori
intoler
convent
therapi
invas
fungal
infect
eg
amphotericin
product
voriconazol
etc
voriconazol
level
supratherapeut
reintroduct
lower
dose
close
monitor
consid
normal
serum
transaminas
h
echinocandin
consid
inferior
singleag
choic
manag
invas
aspergillosi
preliminari
result
phase
clinic
trial
combin
therapi
voriconazol
anidulafungin
placebo
invas
aspergillosi
show
trend
toward
improv
outcom
meet
statist
signific
j
reduct
immunosuppress
advis
especi
taper
withdraw
corticosteroid
possibl
k
use
recombin
human
growth
factor
filgrastim
sargramostim
may
help
popul
primarili
neutropen
patient
prospect
studi
determin
util
granulocyt
transfus
set
ongo
l
surgic
resect
consid
pulmonari
lesion
close
proxim
great
vessel
pericardium
patient
persist
hemoptysi
singl
cavitari
lesion
pericardi
infect
chest
wall
invas
patient
histori
invas
aspergillosi
prior
transplant
receiv
least
week
antifung
therapi
document
partial
complet
respons
therapi
proceed
condit
strong
consider
made
nonmyeloabl
condit
patient
histori
invas
aspergillosi
secondari
prophylaxi
aspergillusact
azol
antifung
voriconazol
posaconazol
given
patient
posttranspl
set
ii
signific
drugdrug
interact
drug
toxic
limit
azol
use
lipidbas
amphotericin
product
echinocandin
use
secondlin
approach
set
aspergillu
candida
speci
common
fungal
infect
encount
hsct
recipi
fungi
consid
patient
popul
mucormycosi
zygomycosi
increasingli
recogn
highli
immun
suppress
hsct
recipi
addit
intens
immun
suppress
regimen
iron
overload
chelat
deferoxamin
predispos
patient
infect
ii
clinic
present
may
includ
angioinvas
infect
lung
skin
brain
andor
widespread
viscer
involv
set
dissemin
diseas
iii
diagnosi
often
requir
tissu
biopsi
though
bronchoscopi
bronchoalveolar
lavag
sometim
inform
set
pulmonari
infect
iv
manag
infect
includ
antifung
therapi
revers
underli
defect
host
defens
possibl
includ
taper
immun
suppress
restor
euglycemia
surgic
debrid
applic
v
liposom
amphotericin
mgkg
iv
daili
firstlin
antifung
therapi
posaconazol
consid
salvag
therapi
patient
intoler
firstlin
therapi
secondari
prophylaxi
voriconazol
activ
mucormycosi
vi
despit
aggress
manag
infect
mortal
rate
remain
high
consult
infecti
diseas
servic
recommend
b
dissemin
fusariosi
seen
highli
immunosuppress
hsct
recipi
often
character
cutan
lesion
posit
blood
cultur
without
viscer
involv
antifung
suscept
vari
speci
treatment
dissemin
infect
either
voriconazol
liposom
amphotericin
indic
fusarium
solani
f
verticillioid
ii
addit
antifung
treatment
manag
includ
surgic
debrid
applic
manuev
improv
host
immun
respons
growth
factor
support
andor
granulocyt
transfus
consid
adjuv
care
persist
neutropen
individu
iii
prognosi
dissemin
diseas
gener
poor
larg
determin
degre
immun
suppress
iv
consult
infecti
diseas
servic
recommend
c
cryptococcosi
report
uncommonli
hsct
popul
may
well
relat
widespread
use
azol
prophylaxi
patient
popul
cryptococc
infect
may
result
pulmonari
central
nervou
system
cutan
wide
dissemin
infect
ii
common
diagnost
modal
includ
cultur
blood
andor
bodi
fluidstissu
antigenbas
test
serum
csf
cryptococc
antigen
diagnost
workup
includ
lumbar
punctur
entiti
consid
iii
manag
liposom
amphotericin
fluconazol
along
serial
lumbar
punctur
manag
elev
intracrani
pressur
context
cryptococc
mening
iv
although
mainstay
combin
therapi
amphotericin
b
formul
hivposit
patient
cryptococc
mening
concurr
use
flucytosin
often
poorli
toler
hsct
recipi
given
potenti
marrow
suppress
v
consult
infecti
diseas
servic
recommend
